My Best Healthcare Stock Picks For 2013 | Last Year’s Picks Gained 31.55%
Last year at this time, I made a screen of some stocks from the healthcare sector with an interesting market valuation, a great past growth performance as well as good earnings situation. Such stocks had a forward price to earnings ratio of less than 15, a sales growth over the past five years of more than 10 percent as well as an operating margin above 10 percent. Exactly seven stocks fulfilled these criteria. Now, I review these picks and try to discover a new list of potential stocks for next year, 2013. Over the recent year the Dow is up 8.36 percent, the S&P 500 gained 13.82 percent and the NASDAQ is 14.58 percent higher. My seven healthcare picks performed in average 31.55 percent while the healthcare sector gained 25.7 percent. Below is a current screen of the seven picks.
(IRIX, MASI, SLXP) Noticeable Stocks by StockHotTips.com
Salix Pharmaceuticals, Ltd emerged as Bullish Stock - NASDAQ:SLXP
Salix Pharmaceuticals, Ltd illustrated Top Momentum - NASDAQ:SLXP
Salix Pharmaceuticals, Ltd Closed in Green - NASDAQ:SLXP
(SLXP, ISTA, CRWE, CNMD) Stock Report from BestOtc.com
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced that the Company will present at The 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 11, 2012 at 4:30 p.m. PT (7:30 p.m. ET). Interested parties can access a live audio web cast of the presentation at http://www.salix.com. A replay of the presentation will be available at the same location.
(CRWE, MAPP, GTIV, SLXP) Stock Updates by DoubleInStocks.com
(CRWE, SONO, SLXP, ICUI) Stocks in Review by CRWEFinance.com
Fulsome Volume of Salix Pharmaceuticals, Ltd - NASDAQ:SLXP
Salix Pharmaceuticals, Ltd (NASDAQ:SLXP) Salix Pharmaceuticals, Ltd. is a pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract.
(CSIQ, PGNX, MSHL, SLXP) PennyOmega.com Stocks In Action
MSHL, Marshall Edwards Inc.
** MSHL reported that the U.S. Patent and Trademark Office has issued a new patent, U.S. Patent No. 8,080,675, covering a number of the Company's isoflavone-based compounds, including lead oncology-drug candidates ME-143 and ME-344, and their pharmaceutical compositions. The patent is estimated to provide protection until March 2027.